Nothing Special   »   [go: up one dir, main page]

AU2002317377A1 - Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer - Google Patents

Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer

Info

Publication number
AU2002317377A1
AU2002317377A1 AU2002317377A AU2002317377A AU2002317377A1 AU 2002317377 A1 AU2002317377 A1 AU 2002317377A1 AU 2002317377 A AU2002317377 A AU 2002317377A AU 2002317377 A AU2002317377 A AU 2002317377A AU 2002317377 A1 AU2002317377 A1 AU 2002317377A1
Authority
AU
Australia
Prior art keywords
apurinic
biphenyl
treat cancer
apyrimidinic site
endonuclease inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002317377A
Inventor
Timothy Robin Hammonds
Ian David Hickson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of AU2002317377A1 publication Critical patent/AU2002317377A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002317377A 2001-07-20 2002-07-22 Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer Abandoned AU2002317377A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30667901P 2001-07-20 2001-07-20
US60/306,679 2001-07-20
PCT/GB2002/003342 WO2003007955A2 (en) 2001-07-20 2002-07-22 Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer

Publications (1)

Publication Number Publication Date
AU2002317377A1 true AU2002317377A1 (en) 2003-03-03

Family

ID=23186355

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002317377A Abandoned AU2002317377A1 (en) 2001-07-20 2002-07-22 Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer

Country Status (2)

Country Link
AU (1) AU2002317377A1 (en)
WO (1) WO2003007955A2 (en)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002252976A1 (en) * 2001-01-22 2002-09-19 Arpida Ag Hydrazones and their therapeutic use
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
AU2003208479A1 (en) 2002-03-09 2003-09-22 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
WO2004110350A2 (en) * 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
WO2004108139A2 (en) * 2003-06-06 2004-12-16 Arexis Ab Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer
WO2005000301A1 (en) * 2003-06-20 2005-01-06 F. Hoffmann-La Roche Ag 2-aminobenzothiazoles as cb1 receptor inverse agonists
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
ES2340179T3 (en) 2004-05-12 2010-05-31 Bristol-Myers Squibb Company UREA ANTAGONISTS OF THE RECEIVER P2Y1 USEFUL IN THE TREATMENT OF THROMBOTIC AFFECTIONS.
TW200606137A (en) * 2004-07-02 2006-02-16 Sankyo Co Urea derivatives
KR101155288B1 (en) * 2004-07-30 2012-07-02 엑셀리시스, 인코포레이티드 Pyrrole Derivatives as Pharmaceutical Agents
KR100784337B1 (en) * 2004-11-12 2007-12-13 한국생명공학연구원 Novel ?-acyloxime derivatives, a process for the preparation thereof and pharmaceutical composition comprising the same for prevention and treatment of cardiovascular disease
WO2006078621A2 (en) 2005-01-19 2006-07-27 Bristol-Myers Squibb Company 2-phenoxy-n- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders
WO2007002635A2 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
DE602006020871D1 (en) 2005-06-27 2011-05-05 Bristol Myers Squibb Co LINEAR UREA MIMETIC ANTAGONISTS OF THE P2Y1 RECEPTOR FOR THE TREATMENT OF THROMBOSELEIDES
ATE505468T1 (en) 2005-06-27 2011-04-15 Bristol Myers Squibb Co N-LINKED HETEROCYCLIC ANTAGONISTS OF THE P2Y1 RECEPTOR FOR THE TREATMENT OF THROMBOSIS
US7714002B2 (en) 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
NZ587586A (en) 2005-07-18 2012-04-27 Bipar Sciences Inc Treatment of cancer
EP1987028A2 (en) 2006-02-10 2008-11-05 Transtech Pharma, Inc. Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
EP2059498A4 (en) 2006-09-05 2011-01-12 Bipar Sciences Inc Treatment of cancer
EP2420498B1 (en) 2006-09-26 2017-05-31 Celgene Corporation 5-substituted quinazolinone derivatives as anti-cancer agents
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP2121687B1 (en) 2006-12-22 2015-10-14 Astex Therapeutics Limited Tricyclic amine derivatives as protein tyrosine kinase inhibitors
US8895745B2 (en) 2006-12-22 2014-11-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as FGFR inhibitors
AU2007339918B2 (en) 2006-12-29 2011-06-02 Tracon Pharmaceuticals, Inc. Antifolate agent combinations in the treatment of cancer
EP1972624A1 (en) * 2007-03-23 2008-09-24 Clariant International Ltd. Benzoxazinones and their use as ultraviolet light absorbers
WO2009041972A1 (en) * 2007-09-27 2009-04-02 University Of Notre Dame Du Lac Antibacterial compounds and methods of using same
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
MX2010005222A (en) 2007-11-12 2010-09-28 Bipar Sciences Inc Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents.
WO2009082398A1 (en) 2007-12-21 2009-07-02 University Of Notre Dame Du Lac Antibacterial compounds and methods of using same
EP2256105B1 (en) 2008-03-26 2013-12-04 Daiichi Sankyo Company, Limited Novel tetrahydroisoquinoline derivative
MX2010012699A (en) 2008-05-23 2010-12-07 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors.
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
ES2438496T3 (en) 2008-08-01 2014-01-17 Ventirx Pharmaceuticals, Inc. Formulations of toll-like receptor agonists and their use
WO2010054215A1 (en) 2008-11-06 2010-05-14 Ventirx Pharmaceuticals, Inc. Methods of synthesis of benzazepine derivatives
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
CN102753542B (en) 2009-08-18 2016-01-20 文蒂雷克斯药品公司 As the benzo-aza * of the replacement of T0LL sample receptor modulators
HUE031797T2 (en) 2009-08-18 2017-08-28 Ventirx Pharmaceuticals Inc Substituted benzoazepines as toll-like receptor modulators
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
PL2575968T3 (en) 2010-06-01 2016-07-29 Summit Oxford Ltd Compounds for the treatment of clostridium difficile associated disease
WO2011156321A1 (en) 2010-06-07 2011-12-15 Novomedix, Llc Furanyl compounds and the use thereof
UY33337A (en) 2010-10-18 2011-10-31 Respivert Ltd SUBSTITUTED DERIVATIVES OF 1H-PIRAZOL [3,4-d] PYRIMIDINE AS INHIBITORS OF PHOSFOINOSITIDE 3-KINASES
GB201020397D0 (en) * 2010-12-02 2011-01-12 Univ Nottingham Compounds
US8802685B2 (en) 2011-03-11 2014-08-12 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
KR20140067048A (en) 2011-08-15 2014-06-03 인터뮨, 인크. Lysophosphatidic acid receptor antagonists
SG10201608528YA (en) 2011-12-21 2016-12-29 Novira Therapeutics Inc Hepatitis b antiviral agents
PE20142342A1 (en) 2012-03-13 2015-01-16 Respivert Ltd CRYSTALLINE FORMS OF 6- (2 - ((4-AMINO-3- (3-HYDROXYPHENYL) -1H-PYRAZOLO [3,4-d] PYRIMIDIN-1-IL) METHYL) -3- (2-CHLOROBENZYL) -4 -OXO-3,4-DIHYDROQUINAZOLINE-5-IL) -N, N-BIS (2-METOXYETHYL) HEX-5-INAMIDE AS INHIBITORS OF PHOSPHOINOSITIDE KINASE 3
WO2014033170A1 (en) 2012-08-28 2014-03-06 Janssen R&D Ireland Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
JP2015531776A (en) 2012-09-04 2015-11-05 セルジーン コーポレイション Isotopologue of 3- (5-amino-2-methyl-4-oxoquinazolin-3 (4H) -yl) piperidine-2,6-dione and process for producing the same
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
CN103664919B (en) * 2012-09-26 2016-02-10 李超 A kind ofly can be used for the compound preparing chemotherapeutics
MX370519B (en) 2012-11-30 2019-12-17 Novomedix Llc Substituted biaryl sulfonamides and the use thereof.
TWI644899B (en) 2013-02-04 2018-12-21 健生藥品公司 Flap modulators
EP3495359A1 (en) 2013-02-04 2019-06-12 Janssen Pharmaceutica NV Flap modulators
US10125094B2 (en) 2013-02-28 2018-11-13 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
WO2014165128A2 (en) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Hepatitis b antiviral agents
JO3279B1 (en) 2013-03-15 2018-09-16 Respivert Ltd 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors
AR095353A1 (en) 2013-03-15 2015-10-07 Respivert Ltd COMPOUND
HUE033542T2 (en) 2013-04-03 2017-12-28 Janssen Sciences Ireland Uc N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JO3603B1 (en) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
SG11201600522UA (en) 2013-07-25 2016-02-26 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
CA2926950C (en) 2013-10-10 2022-10-11 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase
UA117261C2 (en) 2013-10-23 2018-07-10 ЯНССЕН САЙЄНСЕЗ АЙРЛЕНД ЮСі Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
KR20160128305A (en) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Combination therapy for treatment of hbv infections
MX367689B (en) 2014-02-06 2019-09-02 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b.
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
EP3197888A4 (en) 2014-09-25 2018-03-14 University of Notre Dame du Lac Non-beta lactam antibiotics
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
AU2016232801A1 (en) 2015-03-19 2017-10-12 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CA3000197A1 (en) 2015-09-29 2017-04-06 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
CN109640980A (en) 2016-04-15 2019-04-16 诺维拉治疗公司 Combination and method comprising shell assembly inhibitor
US11168062B2 (en) 2016-09-12 2021-11-09 University Of Notre Dame Du Lac Compounds for the treatment of Clostridium difficile infection
PE20201164A1 (en) 2017-07-11 2020-10-28 Vertex Pharma CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS
JP2020536863A (en) 2017-10-06 2020-12-17 フォーマ セラピューティクス，インコーポレイテッド Ubiquitin-specific inhibition of peptidase 30
US10973801B2 (en) 2018-03-14 2021-04-13 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
SG11202011299PA (en) 2018-05-17 2020-12-30 Forma Therapeutics Inc Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
US20230141913A2 (en) * 2018-08-24 2023-05-11 Xeniopro GmbH Phenoxy(hetero)aryl ethers of antiproliferactive activity
WO2020072964A1 (en) 2018-10-05 2020-04-09 Forma Therapeutics, Inc. Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
WO2020169784A1 (en) 2019-02-22 2020-08-27 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases
CN109820850A (en) * 2019-04-10 2019-05-31 广西中医药大学 Application of the α-terthienyl in preparation treatment prostate cancer drug
AR119732A1 (en) 2019-05-06 2022-01-05 Janssen Sciences Ireland Unlimited Co AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES
KR20220157089A (en) * 2021-05-20 2022-11-29 연세대학교 산학협력단 A composition for preventing, alleviating or treating cancer
CN114106586B (en) * 2021-12-13 2022-11-01 江南大学 Schiff base disperse dye with photochromic and fluorescent functions, and preparation method and application thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4183931A (en) * 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
US5496844A (en) * 1992-05-08 1996-03-05 Otsuka Pharmaceutical Factory, Inc. Indole derivatives
SK283413B6 (en) * 1992-08-06 2003-07-01 Warner-Lambert Company 2-Thioindoles, 2-indolinethiones and polysulfides, their analogues (2-indolineselenone) (selenide), and pharmaceutical compositions based on them
US5703130A (en) * 1995-06-07 1997-12-30 Institute Of Materia Medica, An Institute Of The Chinese Academy Of Medical Sciences Chalcone retinoids and methods of use of same
AU702887B2 (en) * 1995-10-31 1999-03-11 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
US5919643A (en) * 1996-06-11 1999-07-06 Advanced Research & Technology Institute Methods and compositions for the use of apurinic/apyrimidinic endonucleases
WO1997049400A1 (en) * 1996-06-27 1997-12-31 Smithkline Beecham Corporation Il-8 receptor antagonists
FR2762841B1 (en) * 1997-04-30 1999-07-02 Jouveinal Inst Rech DIAZEPINO-INDOLONES INHIBITING PHOSPHODIESTERASES IV
US6093742A (en) * 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
CA2315646C (en) * 1997-12-22 2010-02-09 Bayer Corporation Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
ES2153340T3 (en) * 1997-12-22 2006-02-01 Bayer Pharmaceuticals Corp. INHIBITION OF THE QUINASA RAF USING SUBSTITUTED HETEROCICLIC UREAS.
AU2826099A (en) * 1998-03-24 1999-10-18 Novo Nordisk A/S Heterocyclic compounds regulating clotting
EP1073643B1 (en) * 1998-04-23 2004-12-29 Dr. Reddy's Laboratories Ltd. New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
JPH11322611A (en) * 1998-05-14 1999-11-24 Sankyo Co Ltd Antiviral agent
US6337332B1 (en) * 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists
US6187779B1 (en) * 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6225315B1 (en) * 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance
AU2002214546A1 (en) * 2000-09-29 2002-04-08 Cor Therapeutics, Inc. Bicyclic pyrimidin-4-one based inhibitors of factor xa

Also Published As

Publication number Publication date
WO2003007955A2 (en) 2003-01-30
WO2003007955A3 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
AU2002317377A1 (en) Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
AU2002361846A1 (en) Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
AU2002364211A1 (en) Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
AU2002367466A1 (en) Amplification of nucleic acid fragments using nicking agents
AU2003226301A1 (en) Method of treating cancer
AU2003293194A1 (en) Compositions and methods for treating prostate cancer
WO2003101444A8 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
IL157652A (en) Metalloproteinase inhibitors, compositions comprising them and uses thereof for the preparation of medicaments for treating diseases or conditions mediated by metalloproteinase enzymes
ZA200304893B (en) Ether derivatives useful as inhibitors of PDE4 isozymes.
AU2003230750A1 (en) Compositions and methods for treating cancer
AU2002328952A1 (en) Irinotecan for treatment of cancer
MY136037A (en) Biphenyl pyrimidone lp-pla2 inhibitors
AU2002340168A1 (en) Treatment of prostate cancer by inhibitors of ncam2
AU2003256847A8 (en) Method of treating cancer
AU2002367172A1 (en) 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
AUPQ923100A0 (en) Treatment of prostate cancer
AU2003295336A1 (en) Use of etodoclac to treat hyperplasia
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
WO2004032908A3 (en) Method of inhibiting angiogenesis
AU2003260778A1 (en) Treatment of pipes
AU2001232060A1 (en) Use of cyp1b1 inhibitors for treating cancer
AU2002307100A1 (en) Use of tumor necrosis factor inhibitors to treat cardiovascular disease
AU2001253836A1 (en) Method of treating cancer
AU2003280558A1 (en) Method for treatment of cancer
ZA200603153B (en) Pyridine compounds as inhibitors of dipetidyl peptidase IV

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase